NLM Digital Collections

Search

Start Over Subjects Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy ✖Remove constraint Subjects: Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy

1. High cost sharing and specialty drug initiation under Medicare Part D: a case study in patients with newly diagnosed chronic myeloid leukemia

Author(s):
Doshi, Jalpa A., author
Li, Pengxiang, author
Huo, Hairong, author
Pettit, Amy R., author
Kumar, Rishab, author
Weiss, Brendan M., author
Huntington, Scott F., author
Publication:
Philadelphia, PA : Leonard Davis Institute of Health Economics, 2016
Subject(s):
Cost Sharing
Drug Costs
Medicare Part D -- economics
Financing, Personal
Health Services Accessibility
Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy
Protein Kinase Inhibitors -- economics
Protein Kinase Inhibitors -- therapeutic use
Protein-Tyrosine Kinases -- antagonists & inhibitors
Humans
United States

2. Hematologic malignancies: regulatory considerations for use of minimal residual disease in development of drug and biological products for treatment

Publication:
Silver Spring, MD : Center for Drug Evaluation and Research, January 2020
Subject(s):
Biomarkers
Clinical Trials as Topic
Drug Approval
Drug Development
Drugs, Investigational
Hematologic Neoplasms -- drug therapy
Investigational New Drug Application
Neoplasm, Residual
Endpoint Determination
Leukemia, Lymphocytic, Chronic, B-Cell -- drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy
Leukemia, Myeloid, Acute -- drug therapy
Leukemia, Promyelocytic, Acute -- drug therapy
Multiple Myeloma -- drug therapy
Patient Selection
Precursor Cell Lymphoblastic Leukemia-Lymphoma -- drug therapy
Prognosis
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.